LATEST: Ozempic®▼ (semaglutide) for adults living with type 2 diabetes in the UK

Message from Novo Nordisk UK, correct as of 14 June 2023.

Novo Nordisk UK is aware of intermittent stock shortages of Ozempic® ▼(semaglutide)  in the UK. Unprecedented levels of demand for this medicine have tested our manufacturing capacity.  Whilst we continue to increase our capacity significantly, our present supply does not always meet this excess demand, which has led to intermittent supply which is expected to last into 2024.

The shortage is not because of any safety or quality related concern with Ozempic.

During this shortage period, as per DHSC (Department of Health & Social Care) recommendation, no new patients should be initiated on Ozempic so that available stock can be used for existing patients.

We understand the uncertainty and concern this shortage may cause people living with diabetes. This is not something we are taking lightly, and we are working hard to solve these challenges.